Feedback
Benzodiazepines, Urine, Quantitative
2008291
Ordering Recommendation

Preferred test to follow-up presumptive results. For general screening, Benzodiazepines Urine Screen with Reflex to Quantitation (2012225) is preferred.

Mnemonic
CDCO BENZO
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
N/A
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Random urine. 
Specimen Preparation
Transfer 0.5 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 0.3 mL) 
Storage/Transport Temperature
Room temperature. 
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles. 
Remarks
 
Stability
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years 
Reference Interval
Drugs CoveredCutoff Concentrations
Alprazolam5 ng/mL
Alpha-hydroxyalprazolam5 ng/mL
Chlordiazepoxide20 ng/mL
Clonazepam5 ng/mL
7-aminoclonazepam5 ng/mL
Diazepam20 ng/mL
Lorazepam20 ng/mL
Midazolam20 ng/mL
Alpha-hydroxymidazolam20 ng/mL
Nordiazepam20 ng/mL
Oxazepam20 ng/mL
Temazepam20 ng/mL

Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Drugs covered:
alprazolam, alpha-hydroxyalprazolam, chlordiazepoxide, clonazepam, 7-aminoclonazepam, diazepam, lorazepam, midazolam, alpha-hydroxymidazolam, nordiazepam, oxazepam and temazepam..

Positive cutoff:
20 ng/mL unless specified below:
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
7-aminoclonazepam 5 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
CPT Code(s)
80346 (Alt code: G0480)
Components
Component Test Code*Component Chart NameLOINC
2007834Diazepam, Urn, Quant16227-1
2007835Oxazepam, Urn, Quant3886-9
2007836Temazepam, Urn, Quant20559-1
2007837Nordiazepam, Urn, Quant16228-9
2007838Lorazepam, Urn, Quant17088-6
2007839Alprazolam, Urn, Quant59615-5
2007840Alpha-hydroxyalprazolam, Urn, Quant16348-5
2007841Clonazepam, Urn, Quant16229-7
20078427-aminoclonazepam, Urn, Quant51776-3
2007846Midazolam, Urn, Quant16233-9
2007847Chlordiazepoxide, Urn, Quant20522-9
2008511Alpha-hydroxymidazolam, Urn, Quant59590-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Pain Management, Benzodiazepines, Quantitative, w/ medMATCH, Urine (Drugs of Abuse Confirmation/Quan
  • Pain Management, Benzodiazepines, w/Confirmation w/med MATACH, Urine (Drugs of Abuse Confirmation/Qu